AEZS (MC $43 M ) Cash $25 M / 1 Product awaiting FDA approval / 9 Cancer Drugs in P2-3
Check it out guys you have the MEGA opportunity to buy this significantly underpriced stock at the bottom if you want to make money !
AEZS has already a Drug on the Market which is partnered with pharma giant Merck (MRK) , this Product brings around $70 M in annual revenue to AEZS thats almost two times higher than current Market Cap .
AEZS has another Drug awaiting FDA approval and muliple Cancer Drugs in Late Stage some of them have potential Blockbusters .
I think AEZS has the potential for a runup to minimum to $4-5 before FDA decision in Mid 2014 . GL
AEterna Zentaris (AEZS)
Market Cap: $43 M
Cash: $25 M
Shares Out: 32 M
Annual Revenue :$ 70 M
BIG PIPELINE :
Macimorelin Acetate (AEZS-130)
Diagnostic in adult growth hormonedeficiency (endocrinology) Awaiting FDA approval
Product ..Zoptarelin Doxorubicin (AEZS-108)
Endometrial cancer in Phase 3
Tripl-negative breast cancer In Phase 2
Castration-and taxane-resistant prostate cancer in Phase 2